Clinical trial · Interventional
Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer
Compassionate Single Subject Use of FG-3019 in Locally Advanced, Unresectable Pancreatic Cancer (Emergency Use of a Test Article)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The patient passed before treatment could be started
Summary
Brief summary (as posted)
Single compassionate use subject is an 83 year old woman with a history of lymph node positive breast cancer and recently diagnosed pancreatic cancer in May. With an Eastern Cooperative Oncology Group (ECOG) of 2, it is felt that she cannot tolerate more aggressive chemotherapy. The investigators propose to administer FG-3019 on a compassionate pleas basis in combination with gemzar. The patient is currently being treated and is tolerating gemzar.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FG-3019 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- FG-3019
- description
- Treatment of Pancreatic Cancer with FG-3019
- interventionNames
- Drug: FG-3019
Primary outcomes (1)
- measure
- FG-3019 treatment regimen to increase OS (overall survival)
- timeFrame
- 7.7 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 83 Years
- Maximum age
- 83 Years
Show eligibility criteria text
Inclusion Criteria: * Signed Consent form * Have adequate liver function * Have adequate bone marrow function Exclusion Criteria: * History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies * Any medical or surgical condition that may place the subject at increased risk while on treatment * Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with treatment requirements * Current abuse of alcohol or drugs
References
Publications (0)
Data not yet available